ReviewActa pharmaceutica Sinica. B2019
Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application.
Review in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 275 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
275 citing papers in PubMed, 1 synthesis or guideline pooled it, 618 citations in OpenAlex.
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.Nature communications · 2024Pooled it
- Biomimetic co-delivery nanoplatform overcomes CAF- and TAM-induced immunosuppression to augment therapeutic efficacy against triple-negative breast cancer.International journal of pharmaceutics: X · 2026Article
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Ultrasound‑responsive nano‑contrast agents co‑delivering CIITA ‑siRNA and rapamycin for targeted therapy against Hashimoto thyroiditis.Chinese medical journal · 2026Article
- Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- From Design to Bedside: Brain-Targeted Engineered Nanoparticles and Predictive Modeling for Neurodegenerative Diseases Therapeutics.Pharmaceutical research · 2026Review
- Targeting the BACE1-GSK-3β Signaling Axis in Alzheimer's Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies.Molecular neurobiology · 2026Review
- Engineering Red Blood Cell Membrane-Coated PLGA Nanoparticles for Kahweol Delivery: Formulation Development and Pharmacokinetic Assessment.Molecules (Basel, Switzerland) · 2026Article
- Cell Membrane-Coated Biomimetic Nanocarriers for Plaque-Targeted Atherosclerosis Therapy: Molecular Mechanisms, Inflammatory Microenvironments, and Translational Challenges.International journal of molecular sciences · 2026Review
- Blood Cell-Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING-Amplified Photothermal Immunity for Metastatic Triple-Negative Breast Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Surface bioengineering of lanthanide nanoparticles for theranostic applications: From hydrophilic modification to multimodal imaging and therapy.Materials today. Bio · 2026Review
- Microglia-Targeted Biomimetic Tetrahedral Framework Nucleic Acid Nanovesicles for Synergistic Treatment of Sepsis-Associated Encephalopathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.Bioengineering (Basel, Switzerland) · 2026Review
- Advances in nano-TCM for Alzheimer's disease: lipid-based carriers integrated with innovative delivery strategies.Journal of nanobiotechnology · 2026Review
- Engineered Cell Membrane-Coated Nanoparticles: A New Strategy for Pancreatic Cancer Therapy.ACS pharmacology & translational science · 2026Review
- Nanotechnology-based detoxification of profenofos using red blood cell membrane-coated polymeric nanoparticles.BMC pharmacology & toxicology · 2026Article
- HJournal of nanobiotechnology · 2026Article
- PEGylated gold nanoparticles regulate metabolic flux in erythrocytes by inducing hemoglobin deoxygenation.International journal of pharmaceutics: X · 2026Article
- Allicin-based biomimetic nanoparticles of the erythrocyte membrane for the delivery of lumefantrine to enhance its antimalarial effect.International journal of pharmaceutics: X · 2026Article
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
215 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythrocytes (red blood cells, RBCs) are the most abundant circulating cells in the blood and have been widely used in drug delivery systems (DDS) because of their features of biocompatibility, biodegradability, and long circulating half-life. Accordingly, a "camouflage" comprised of erythrocyte membranes renders nanoparticles as a platform that combines the advantages of native erythrocyte membranes with those of nanomaterials. Following injection into the blood of animal models, the coated nanoparticles imitate RBCs and interact with the surroundings to achieve long-term circulation. In this review, the biomimetic platform of erythrocyte membrane-coated nano-cores is described with regard to various aspects, with particular focus placed on the coating mechanism, preparation methods, verification methods, and the latest anti-tumor applications. Finally, further functional modifications of the erythrocyte membranes and attempts to fuse the surface properties of multiple cell membranes are discussed, providing a foundation to stimulate extensive research into multifunctional nano-biomimetic systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.